会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Drug dispensing wound dressing
    • 药物分配伤口敷料
    • US4614787A
    • 1986-09-30
    • US670810
    • 1984-11-13
    • Michael SzycherDonald J. DempseyJonathan L. Rolfe
    • Michael SzycherDonald J. DempseyJonathan L. Rolfe
    • A61F13/15A61L15/26A61L15/44C08G18/10A61F13/00
    • A61L15/44A61L15/26A61F2013/530007A61L2300/402A61L2300/404A61L2300/41A61L2300/418
    • The disclosed wound dressings have a drug dispersed throughout a polyurethane matrix that is the reaction product of: (A) An isocyante terminated prepolymer formed by reaction of isophorone diisocyanate and a macroglycol and (B) a monomer containing hydroxyl and vinyl groups. The reaction product is a vinyl terminated polyurethane oligomer which is liquid at room temperature and which may be readily admixed with a pharmacoactive substance and a photosensitizer, formed into a film and cured by exposure to UV light without release of heat.In the most preferred embodiments the foregoing oligomer is codissolved in an organic solvent with a polyurethane polymer which is the reaction product of:dicyclohexyl methane diisocyanate;a polytetramethylene ether polyol having a molecular weight in the range of 1000-3000 daltons; and1,4-butane diol.That solution is then admixed with the pharmacoactive agent, formed into a film and cured.
    • 所公开的伤口敷料具有分散在整个聚氨酯基质中的药物,其是以下物质的反应产物:(A)通过异佛尔酮二异氰酸酯和大分子二醇反应形成的异氰酸酯封端的预聚物和(B)含有羟基和乙烯基的单体。 反应产物是在室温下为液体的乙烯基封端的聚氨酯低聚物,其可以容易地与药物活性物质和光敏剂混合,形成膜并通过暴露于UV光而不释放热而固化。 在最优选的实施方案中,上述低聚物与聚氨酯聚合物共同存在于有机溶剂中,所述聚氨酯聚合物是以下物质的反应产物:二环己基甲烷二异氰酸酯; 分子量为1000-3000道尔顿的聚四亚甲基醚多元醇; 和1,4-丁二醇。 然后将该溶液与药物活性剂混合,形成膜并固化。
    • 3. 发明授权
    • Medical patches and processes for producing same
    • 医疗补丁和生产方法
    • US4751133A
    • 1988-06-14
    • US053496
    • 1987-05-11
    • Michael SzycherJonathan L. Rolfe
    • Michael SzycherJonathan L. Rolfe
    • A61F13/15A61L15/26A61L15/44B05D3/02B32B7/00D04B1/00
    • A61L15/44A61L15/26A61F2013/530007A61L2300/00Y10S428/913Y10T428/28Y10T428/2848Y10T442/10
    • A layer or member particularly useful as part of a medical patch such as an anisotropic wound dressing, a transdermal skin patch or an incise medical drape and the processes for forming such a member. The member is comprised of a crosslinked thermoset aliphatic polyurethane elastomer. The elastomer is the reaction product of (1) isophorone diisocyanate, (2) a macroglycol and (3) a chain terminator having both hydroxyl and vinyl functional groups. Polycarbonate glycols or polyetherglycols having a molecular weight of 500-2500 Daltons are preferred macroglycols and isophorone diamine is a preferred chain terminator. In one embodiment, a member or polyurethane layer for use as a wound dressing or an incise medical drape is produced by applying a film-forming solution or dispersion as a thin film to a supporting release paper and treating the film to drive off the liquids and to activate a crosslinker. In another embodiment, a member for an anisotropic medical patch is produced by sandwiching a knitted reinforcing fabric in the elastomer. When used as a transdermal skin patch or a drug dispensing wound dressing, a layer of drug dispensing film containing pharmacoactive agents may be applied to the medical patch, and when appropriate, the medical patch may be coated with a pressure sensitive adhesive.
    • 特别适用于诸如各向异性伤口敷料,透皮贴剂或切开医用罩的医疗贴剂的一部分的层或构件以及用于形成这种构件的方法。 该构件由交联的热固性脂族聚氨酯弹性体组成。 弹性体是(1)异佛尔酮二异氰酸酯,(2)大分子二醇和(3)具有羟基和乙烯基官能团的链终止剂的反应产物。 分子量为500-2500道尔顿的聚碳酸酯二醇或聚醚二醇是优选的大分子二聚体,异佛尔酮二胺是优选的链终止剂。 在一个实施方案中,通过将薄膜形成溶液或分散体作为薄膜施加到支持性剥离纸上并且处理该膜以驱除液体而产生用作伤口敷料或切割医用覆盖物的构件或聚氨酯层, 以激活交联剂。 在另一个实施例中,通过将针织增强织物夹在弹性体中来制造用于各向异性医疗贴剂的构件。 当用作透皮贴剂或药物分配伤口敷料时,可将含有药物活性剂的药物分配膜层施加到医用贴剂上,并且在合适的时候可以用压敏粘合剂涂覆医用贴剂。
    • 4. 发明授权
    • Drug release system
    • 药物释放系统
    • US4638043A
    • 1987-01-20
    • US768623
    • 1985-08-23
    • Michael SzycherDonald J. DempseyJonathan L. Rolfe
    • Michael SzycherDonald J. DempseyJonathan L. Rolfe
    • A61M37/00A61F13/15A61K9/22A61K9/70A61L15/26A61L15/44C08G18/44C08G18/67C08G18/10A61F13/00
    • A61K9/7084A61L15/26A61L15/44C08G18/44C08G18/672A61F2013/530007A61K9/703A61L2300/608
    • A drug releasing system in the form of a medical patch comprised of a drug dispensing polyurethane member as a matrix for a therapeutically effective amount of drug dispersed therein. The polyurethane of the drug dispensing or releasing member is a polyurethane acrylic copolymer which is the reaction product of an oligomer of a diisocyanate, a glycol with a molecular weight between the range of 500-5,000 molecular weight units and an acrylyl chain terminator having a molecular weight between the range of 40-200 molecular weight units cured by actinic radiation. In its preferred embodiment, the foregoing drug releasing or dispensing member is incorporated into a medical patch or drug release system comprised of successive layers of an ultrathin polyurethane substrate, pressure sensitive adhesive, the above-described drug releasing member and optionally a second layer of adhesive.The drug release system of the present invention is biocompatible, oxygen and water vapor permeable, flexible and can incorporate a wide variety of drugs for a controlled, sustained release to the wearer.
    • 医药贴剂形式的药物释放系统,其由作为基质的药物分配聚氨酯部件组成,用于分散在其中的治疗有效量的药物。 药物分配或释放构件的聚氨酯是聚氨酯丙烯酸共聚物,其是二异氰酸酯的低聚物,分子量在500-5,000分子量单元范围内的二醇与具有分子量的丙烯酰链终止剂之间的反应产物 通过光化辐射固化的40-200分子量单位的范围之间的重量。 在其优选的实施方案中,将上述药物释放或分配构件并入由超薄聚氨酯基材,压敏粘合剂,上述药物释放组件和任选的第二层粘合剂的连续层组成的医疗补片或药物释放系统中 。 本发明的药物释放系统是生物相容性的,氧气和水蒸气可透过的,柔性的,并且可以掺入多种用于对受试者持续释放的药物。
    • 10. 发明授权
    • Integrity-enhanced thermoelectrics
    • 完整的增强型热电
    • US5209786A
    • 1993-05-11
    • US594850
    • 1990-10-09
    • Jonathan L. RolfeJohn S. Beaty
    • Jonathan L. RolfeJohn S. Beaty
    • H01L35/32
    • H01L35/32
    • Disclosed are integrity-enhanced thermoelectric devices and methods of their preparation. Such devices have the following characteristics: (1) there is, on average, no greater than about 10% incidence of function loss (failure) of the device on application to the device of a substantial impact or distortion force or corrosion exposure, and (2) the device have at least about 85% of the thermal performance of thermoelectric devices without integrity enhancement (i.e., thermal conductivity across the integrity-enhanced devices is significantly less than 0.0021 Cal-Cm/Cm.sup.2 Sec .degree.C., and is less than or equal to about 0.0015 Cal-Cm/Cm.sup.2 Sec .degree.C.; empirically expressed as maintenance of at least a 40.degree. C. temperature differential over the intra-plate distance which is about 3/16 to about 1/4 of an inch.). Integrity enhancement techniques are described, including the method of embedding components of standard thermoelectric devices in syntactic foam materials, such as those formed of resins and balloon elements.